[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Email: xubinghe@csco.org.cn.
Xiu Bing-He
D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control*; D017698:Postmenopause; D014807:Vitamin D / Q000627:therapeutic use; D000077211:Zoledronic Acid
D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D014807:Vitamin D; D000077211:Zoledronic Acid; D002118:Calcium